Streetbeat News

Products Services

CRL

Charles River Laboratories International, Inc. (CRL) has extended its gene therapy manufacturing alliance with the National University of Singapore's Yong Loo Lin School of Medicine. This partnership aims to advance gene therapy research and manufacturing capabilities.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:04 pm

VRTX

Vertex Pharmaceuticals has received FDA clearance for its Investigational New Drug application for VX-407, aimed at treating Autosomal Dominant Polycystic Kidney Disease. The company plans to begin a Phase 1 clinical trial with healthy volunteers within the month.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:03 pm

LSTA

Lisata Therapeutics has received a Rare Pediatric Disease Designation from the US FDA for LSTA1, aimed at treating Osteosarcoma. This designation could potentially expedite the development and review process for LSTA1, enhancing Lisata Therapeutics' position in the market for rare pediatric diseases.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 12:02 pm

PZZA

Papa John's International is progressing with its Back to Better 2.0 growth strategy, aiming for a 2024 Adjusted Operating Income of $153M-$163M. The strategy includes marketing investments, new franchisee incentives, and international brand transformation. The company expects over 20% increase in North America net unit growth and 100-140 new international restaurants.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:46 am

LMT

MRCY

Mercury Systems and Lockheed Martin are collaborating to advance defense manufacturing capabilities in Switzerland, as part of an offset program related to Switzerland's purchase of the F-35 Lightning II. Mercury will manufacture embedded computing technologies in Geneva, with potential for further expansion.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:40 am

PHIO

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced it will present new data on its INTASYL siRNA gene silencing technology at the 10th Immunotherapy of Cancer Conference (ITOC10) in Munich, Germany, from March 21-23, 2024. The technology aims to enhance the effectiveness of immune cells in killing tumor cells, potentially improving cell therapy for hematological malignancies.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:38 am

BA

EADSY

JPNRF

Japan Airlines Co Ltd (OTC:JPNRF) announced plans to purchase 42 new aircraft from Boeing Company (NYSE:BA) and Airbus SE (OTC:EADSY) for fleet renewal, focusing on growth in North America, Asia, and India. The order includes 21 Airbus A350-900, 11 A321neo, and 10 Boeing 787-9 aircraft, with deliveries starting in fiscal 2027. This move aims to expand JAL's full-service and low-cost carriers by about 1.4 times by 2030.

Portfolio Pulse from Shivani Kumaresan

March 21, 2024 | 11:30 am

AVGO

MU

NVDA

Jim Cramer, host of CNBC's 'Mad Money', has expressed optimism about the prospects of Micron Technology, Inc. (MU) and NVIDIA Corporation (NVDA), suggesting their stock prices could rise further. He recommended buying shares of Nvidia and Broadcom (AVGO), highlighting Micron's role in the AI space and its high bandwidth business essential for AI accelerators like Nvidia's Tensor Core H 200 and Blackwell. This comes as Micron initiated large-scale production of high-bandwidth memory semiconductors for Nvidia's new AI chip, expected to drive significant revenue growth.

Portfolio Pulse from Benzinga Neuro

March 21, 2024 | 11:21 am

GAME

GameSquare Holdings, Inc. (NASDAQ:GAME) celebrates FaZe Clan's success with their energy drink FaZe Pop, which became the top-selling new energy product in 7Eleven for 2023, achieving its best sales month in February 2024. FaZe Clan, acquired by GameSquare, excels in engaging gamers through strategic brand partnerships and licensing deals, expanding their global audience.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:19 am

IFRX

InflaRx plans to target chronic spontaneous urticaria and hidradenitis suppurativa with its INF904 drug, initiating a Phase 2a PK dose-ranging study by the end of 2024. Results from the study are expected to be available in 2025.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 11:15 am